Altimmune (NASDAQ:ALT) Research Coverage Started at Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Altimmune (NASDAQ:ALT) in a research note issued to investors on Wednesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $18.00 target price on the stock.

Several other research firms have also recently commented on ALT. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Thursday, November 14th. UBS Group assumed coverage on Altimmune in a research note on Tuesday, November 12th. They issued a “buy” rating and a $26.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $19.71.

Altimmune Trading Down 7.8 %

NASDAQ:ALT opened at $6.87 on Wednesday. The firm has a market capitalization of $488.63 million, a price-to-earnings ratio of -4.43 and a beta of 0.22. The business’s 50-day moving average price is $8.10 and its two-hundred day moving average price is $7.20. Altimmune has a 1-year low of $5.28 and a 1-year high of $14.84.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million for the quarter. During the same quarter last year, the firm earned ($0.39) EPS. Sell-side analysts predict that Altimmune will post -1.36 earnings per share for the current year.

Institutional Trading of Altimmune

Several institutional investors and hedge funds have recently modified their holdings of the business. B. Riley Wealth Advisors Inc. raised its position in Altimmune by 12.9% in the third quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock valued at $144,000 after purchasing an additional 2,687 shares during the last quarter. Virtu Financial LLC bought a new position in Altimmune in the third quarter valued at about $674,000. Barclays PLC raised its position in Altimmune by 93.0% in the third quarter. Barclays PLC now owns 155,741 shares of the company’s stock valued at $956,000 after purchasing an additional 75,064 shares during the last quarter. Geode Capital Management LLC raised its position in Altimmune by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after purchasing an additional 74,194 shares during the last quarter. Finally, Wellington Management Group LLP raised its position in Altimmune by 27.5% in the third quarter. Wellington Management Group LLP now owns 197,232 shares of the company’s stock valued at $1,211,000 after purchasing an additional 42,553 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.